Cenerimod

Cenerimod
Clinical data
Other namesACT-334441
Legal status
Legal status
  • Investigational
Identifiers
  • (2S)-3-[4-[5-(2-cyclopentyl-6-methoxypyridin-4-yl)-1,2,4-oxadiazol-3-yl]-2-ethyl-6-methylphenoxy]propane-1,2-diol
CAS Number
PubChem CID
IUPHAR/BPS
DrugBank
ChemSpider
UNII
KEGG
ChEMBL
Chemical and physical data
FormulaC25H31N3O5
Molar mass453.539 g·mol−1
3D model (JSmol)
  • CCC1=C(C(=CC(=C1)C2=NOC(=N2)C3=CC(=NC(=C3)OC)C4CCCC4)C)OC[C@H](CO)O
  • InChI=1S/C25H31N3O5/c1-4-16-10-18(9-15(2)23(16)32-14-20(30)13-29)24-27-25(33-28-24)19-11-21(17-7-5-6-8-17)26-22(12-19)31-3/h9-12,17,20,29-30H,4-8,13-14H2,1-3H3/t20-/m0/s1
  • Key:KJKKMMMRWISKRF-FQEVSTJZSA-N

Cenerimod is an investigational new drug that is being evaluated for the treatment of systemic lupus erythematosus.[1] It is a sphingosine-1-phosphate receptor modulator.[2]

References

  1. ^ "Cenerimod - Idorsia Pharmaceuticals". AdisInsight. Springer Nature Switzerland AG.
  2. ^ Piali L, Birker-Robaczewska M, Lescop C, Froidevaux S, Schmitz N, Morrison K, et al. (December 2017). "Cenerimod, a novel selective S1P1 receptor modulator with unique signaling properties". Pharmacology Research & Perspectives. 5 (6). doi:10.1002/prp2.370. PMC 5723703. PMID 29226621.
Stub icon

This pharmacology-related article is a stub. You can help Wikipedia by expanding it.